Imiglucerase manufacturers

Filters

None products found

imiglucerase

Powder for solution for infusion 400 U

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Algeria
GMP approvals
FDA
Manufacturer #38527

The company is a pharmaceutical manufacturer engaged in the development, manufacture and marketing of a wide range of pharmaceutical products for human therapeutic use, operating with global manufacturing capabilities and quality systems to produce and distribute these pharmaceutical products to healthcare providers and markets domestically and internationally.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

About imiglucerase

Imiglucerase manufacturers include the originator Sanofi (Cerezyme, developed by Genzyme) and biosimilar producers such as ISU Abxis in Korea. Imiglucerase is a recombinant form of the enzyme glucocerebrosidase. It is used as long-term enzyme replacement therapy for Gaucher disease, an inherited disorder in which a fatty substance builds up in the spleen, liver and bones. Pharmaceutical companies can source imiglucerase through supply, biosimilar licensing or technology transfer.

Imiglucerase key facts

Property

Imiglucerase

INN

Imiglucerase

Molecule type

Recombinant human glucocerebrosidase (acid beta-glucosidase), made in CHO cells, with mannose-terminated glycans

ATC code

A16AB02

Drug class

Enzyme replacement therapy

Brand name

Cerezyme

Originator

Genzyme, now Sanofi

Biosimilar

Abcertin (ISU Abxis, Korea)

Dosage form and strength

Powder for concentrate for solution for infusion, 400 U vial

Dose

Individualised; typically 2.5–60 U/kg every 2 weeks by intravenous infusion

Indications

Gaucher disease type 1 (and non-neurological symptoms of type 3 in the EU)

First approval

US FDA, 1994 (replacing placenta-derived alglucerase)

Competing therapies

Velaglucerase alfa (VPRIV); taliglucerase alfa (Elelyso); oral eliglustat and miglustat

Biosimilar status

Approved in Korea and some other markets; none in the US or EU

Imiglucerase manufacturers and licensing history

Genzyme first developed alglucerase (Ceredase), extracted from human placentas, and replaced it with recombinant imiglucerase (Cerezyme), approved by the FDA in 1994. Cerezyme became the standard treatment for Gaucher disease. Sanofi acquired Genzyme in 2011.

In 2009, a virus contamination at Genzyme's Allston plant caused a global Cerezyme shortage, which sped up approval of competitors such as Takeda's velaglucerase alfa and Pfizer/Protalix's taliglucerase alfa. Oral substrate reduction therapies, eliglustat and miglustat, are also available.

ISU Abxis developed Abcertin, an imiglucerase biosimilar approved in Korea. Buyers should confirm glycan profile, enzyme activity, comparability data, GMP status and cold-chain capability before choosing a partner.

Imiglucerase dosage forms and dossier types

Imiglucerase is supplied as lyophilised powder in 400 U vials, reconstituted and diluted for intravenous infusion.

Form

Strengths

Typical dossier

Notes

Imiglucerase powder for infusion

400 U vial

US BLA; EU MAA; national biosimilar

Reference Cerezyme

Imiglucerase drug substance

Bulk

Biologics master file

Mannose-terminated glycans required for uptake

Target market

Dossier format

Key requirement

United States

BLA / 351(k)

No biosimilar approved

European Union

Biosimilar MAA

Comparability to Cerezyme

Korea, other markets

National biosimilar pathway

Abcertin approved in Korea

Imiglucerase regulatory and patent status

Imiglucerase was approved in the US in 1994 and is long off-patent. Biosimilars are approved in Korea and some other markets, but not in the US or EU. Gaucher disease is rare, so products hold orphan designations and are often supplied through specialist programmes.

Imiglucerase mechanism of action and therapeutic use

In Gaucher disease, lack of glucocerebrosidase causes glucocerebroside to build up in macrophages, enlarging the spleen and liver and damaging bones and blood counts. Imiglucerase replaces the missing enzyme. Its mannose-terminated sugars target it to macrophages through mannose receptors. It is given by infusion every 2 weeks, usually for life.

Imiglucerase licensing and sourcing

Imiglucerase suppliers and licensing partners typically offer finished-product supply, biosimilar licensing or technology transfer. Buyers usually compare GMP status, comparability data, cold-chain capability and territory availability. Current offers and supplier contacts are listed among the imiglucerase manufacturers on Pipelinepharma.

Frequently asked questions about imiglucerase

Who manufactures imiglucerase? Sanofi makes Cerezyme, developed by Genzyme. ISU Abxis makes the biosimilar Abcertin in Korea.

What is imiglucerase used for? Imiglucerase is used as enzyme replacement therapy for Gaucher disease type 1, and for non-neurological symptoms of type 3 in the EU.

What forms and strengths of imiglucerase are available? Imiglucerase is available as a 400 U lyophilised powder for intravenous infusion.

Is there a biosimilar of imiglucerase? Yes, in Korea (Abcertin) and some other markets. None is approved in the US or EU.

What other treatments exist for Gaucher disease? Other enzyme therapies include velaglucerase alfa and taliglucerase alfa. Oral options include eliglustat and miglustat.

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.